Review



otenabant  (Pfizer Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Pfizer Inc otenabant
    Otenabant, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/otenabant/otenabant/pm38887179-176-46-47
    Average 90 stars, based on 1 article reviews
    otenabant - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity
    Article Snippet: Otenabant, another brain-penetrant CB1R antagonist/inverse agonist, is a purine derivative developed by Pfizer.

    Article Title: Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity.
    Article Snippet: Otenabant, another brain-penetrant CB1R antagonist/inverse agonist, is a purine derivative developed by Pfizer.

    Article Title: Blocking Alcoholic Steatosis in Mice with a Peripherally Restricted Purine Antagonist of the Type 1 Cannabinoid Receptor
    Article Snippet: 6 The adverse side effects seen with 1 precipitated the withdrawal of other CNS-penetrating hCB1 antagonists from clinical development, including otenabant ( 2 ), a compound developed by Pfizer.

    Article Title: Peripherally Selective CB1 Receptor Antagonist Improves Symptoms of Metabolic Syndrome in Mice
    Article Snippet: While the compound demonstrated significant clinical efficacy and arguably a better side-effect profile in patients, its development was discontinued by Pfizer due to regulatory concerns.

    Article Title: Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile.
    Article Snippet: Although rimonabant was the only CB1 inverse agonist submitted for FDA review, several others were in clinical development at the time, including two in phase 3 studies: taranabant (Merck, NCT00131404 [high-dose study, n = 2502 patients] and NCT00420589 [low-dose study, n = 624]) [27, 28] and otenabant (Pfizer, NCT00483171, NCT00391196, NCT00396448, and NCT00375401; n = 5463 total patients).

    Clinical Proteomics:

    Article Title: Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge.
    Article Snippet: .. As a consequence, clinical trials with rimonabant and almost all other CB1R antagonists with similar inverse agonist profiles such as the longer acting second generation surinabant (SR147778, Sanofi-Aventis), ibipinabant (SLV319, Solvay Pharmaceutical), taranabant (MK-0364, Merck), and otenabant (CP-945,598, Pfizer) [102] were terminated worldwide in 2008 [97,99]. ..



    Similar Products

    proteinase k  (MedChemExpress)
    94
    MedChemExpress proteinase k
    ASCs-ApoVs exhibited cross-species conservation and robust environmental resilience. ( A ) Western blot analysis of myofibroblast-related markers in HS-fibroblasts with freezing-thawing (for 3 times) ASCs-ApoVs, freezing-thawing ASCs-ApoVs with additional DNase I treatment, freezing-thawing ASCs-ApoVs with additional RNase A treatment. ( B ) Quantification of ( a ) COL1A1, ( b ) COL3A1, ( c ) COL3A1/COL1A1, ( d ) α-SMA, ( e ) CDC20, ( f ) Vimentin, and ( g ) TGF-β1 expression from ( A ) section by relative gray vale to GAPDH and the control group. (Mean ± SD, n = 3 independent experiments, data analyzed by one-way ANOVA with Tukey’s HSD.) ( C ) RT-qPCR results of ( a ) COL1A1 , ( b ) COL3A1 , ( c ) COL3A1/COL1A1 , ( d ) ACTA2 , ( e ) CDC20 , ( f ) VIM , and ( g ) TGFB1 in HS-fibroblasts with processed ASCs-ApoVs treatment (ASCs-ApoVs freezing-thawing for 3 times, freezing-thawing ASCs-ApoVs with additional DNase I treatment, freezing-thawing ASCs-ApoVs with additional RNase A treatment, freezing-thawing ASCs-ApoVs with additional <t>Proteinase</t> <t>K</t> treatment), normalized to GAPDH and the control group. (Mean ± SD, n = 3 independent experiments, data analyzed by one-way ANOVA with Tukey’s HSD.) ( D ) Western blot analysis of CDC20 expression in normal human fibroblasts (BJ-fibroblasts), human keratinocytes (HaCaT cells), and mouse oral mucosa epithelial cells. ( E ) Quantification of CDC20 expression from ( D ) section by relative gray vale to GAPDH/β-actin. (Mean ± SD, n = 3 independent experiments, data analyzed by Independent-samples t -test.) Statistical significance: ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Proteinase K, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/otenabant/Otenabant/pmc13204812-143-16-18
    Average 94 stars, based on 1 article reviews
    proteinase k - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    otenabant  (TargetMol)
    91
    TargetMol otenabant
    ASCs-ApoVs exhibited cross-species conservation and robust environmental resilience. ( A ) Western blot analysis of myofibroblast-related markers in HS-fibroblasts with freezing-thawing (for 3 times) ASCs-ApoVs, freezing-thawing ASCs-ApoVs with additional DNase I treatment, freezing-thawing ASCs-ApoVs with additional RNase A treatment. ( B ) Quantification of ( a ) COL1A1, ( b ) COL3A1, ( c ) COL3A1/COL1A1, ( d ) α-SMA, ( e ) CDC20, ( f ) Vimentin, and ( g ) TGF-β1 expression from ( A ) section by relative gray vale to GAPDH and the control group. (Mean ± SD, n = 3 independent experiments, data analyzed by one-way ANOVA with Tukey’s HSD.) ( C ) RT-qPCR results of ( a ) COL1A1 , ( b ) COL3A1 , ( c ) COL3A1/COL1A1 , ( d ) ACTA2 , ( e ) CDC20 , ( f ) VIM , and ( g ) TGFB1 in HS-fibroblasts with processed ASCs-ApoVs treatment (ASCs-ApoVs freezing-thawing for 3 times, freezing-thawing ASCs-ApoVs with additional DNase I treatment, freezing-thawing ASCs-ApoVs with additional RNase A treatment, freezing-thawing ASCs-ApoVs with additional <t>Proteinase</t> <t>K</t> treatment), normalized to GAPDH and the control group. (Mean ± SD, n = 3 independent experiments, data analyzed by one-way ANOVA with Tukey’s HSD.) ( D ) Western blot analysis of CDC20 expression in normal human fibroblasts (BJ-fibroblasts), human keratinocytes (HaCaT cells), and mouse oral mucosa epithelial cells. ( E ) Quantification of CDC20 expression from ( D ) section by relative gray vale to GAPDH/β-actin. (Mean ± SD, n = 3 independent experiments, data analyzed by Independent-samples t -test.) Statistical significance: ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Otenabant, supplied by TargetMol, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/otenabant/Otenabant/pm36709687-52-31-32
    Average 91 stars, based on 1 article reviews
    otenabant - by Bioz Stars, 2026-11
    91/100 stars
    		  Buy from Supplier
    cp 945598 hcl otenabant  (MedChemExpress)
    94
    MedChemExpress cp 945598 hcl otenabant
    ASCs-ApoVs exhibited cross-species conservation and robust environmental resilience. ( A ) Western blot analysis of myofibroblast-related markers in HS-fibroblasts with freezing-thawing (for 3 times) ASCs-ApoVs, freezing-thawing ASCs-ApoVs with additional DNase I treatment, freezing-thawing ASCs-ApoVs with additional RNase A treatment. ( B ) Quantification of ( a ) COL1A1, ( b ) COL3A1, ( c ) COL3A1/COL1A1, ( d ) α-SMA, ( e ) CDC20, ( f ) Vimentin, and ( g ) TGF-β1 expression from ( A ) section by relative gray vale to GAPDH and the control group. (Mean ± SD, n = 3 independent experiments, data analyzed by one-way ANOVA with Tukey’s HSD.) ( C ) RT-qPCR results of ( a ) COL1A1 , ( b ) COL3A1 , ( c ) COL3A1/COL1A1 , ( d ) ACTA2 , ( e ) CDC20 , ( f ) VIM , and ( g ) TGFB1 in HS-fibroblasts with processed ASCs-ApoVs treatment (ASCs-ApoVs freezing-thawing for 3 times, freezing-thawing ASCs-ApoVs with additional DNase I treatment, freezing-thawing ASCs-ApoVs with additional RNase A treatment, freezing-thawing ASCs-ApoVs with additional <t>Proteinase</t> <t>K</t> treatment), normalized to GAPDH and the control group. (Mean ± SD, n = 3 independent experiments, data analyzed by one-way ANOVA with Tukey’s HSD.) ( D ) Western blot analysis of CDC20 expression in normal human fibroblasts (BJ-fibroblasts), human keratinocytes (HaCaT cells), and mouse oral mucosa epithelial cells. ( E ) Quantification of CDC20 expression from ( D ) section by relative gray vale to GAPDH/β-actin. (Mean ± SD, n = 3 independent experiments, data analyzed by Independent-samples t -test.) Statistical significance: ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Cp 945598 Hcl Otenabant, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/otenabant/Otenabant/bio_rxiv__64898__2026__04__28__720360-35-0-9
    Average 94 stars, based on 1 article reviews
    cp 945598 hcl otenabant - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    otenabant  (Pfizer Inc)
    90
    Pfizer Inc otenabant
    ASCs-ApoVs exhibited cross-species conservation and robust environmental resilience. ( A ) Western blot analysis of myofibroblast-related markers in HS-fibroblasts with freezing-thawing (for 3 times) ASCs-ApoVs, freezing-thawing ASCs-ApoVs with additional DNase I treatment, freezing-thawing ASCs-ApoVs with additional RNase A treatment. ( B ) Quantification of ( a ) COL1A1, ( b ) COL3A1, ( c ) COL3A1/COL1A1, ( d ) α-SMA, ( e ) CDC20, ( f ) Vimentin, and ( g ) TGF-β1 expression from ( A ) section by relative gray vale to GAPDH and the control group. (Mean ± SD, n = 3 independent experiments, data analyzed by one-way ANOVA with Tukey’s HSD.) ( C ) RT-qPCR results of ( a ) COL1A1 , ( b ) COL3A1 , ( c ) COL3A1/COL1A1 , ( d ) ACTA2 , ( e ) CDC20 , ( f ) VIM , and ( g ) TGFB1 in HS-fibroblasts with processed ASCs-ApoVs treatment (ASCs-ApoVs freezing-thawing for 3 times, freezing-thawing ASCs-ApoVs with additional DNase I treatment, freezing-thawing ASCs-ApoVs with additional RNase A treatment, freezing-thawing ASCs-ApoVs with additional <t>Proteinase</t> <t>K</t> treatment), normalized to GAPDH and the control group. (Mean ± SD, n = 3 independent experiments, data analyzed by one-way ANOVA with Tukey’s HSD.) ( D ) Western blot analysis of CDC20 expression in normal human fibroblasts (BJ-fibroblasts), human keratinocytes (HaCaT cells), and mouse oral mucosa epithelial cells. ( E ) Quantification of CDC20 expression from ( D ) section by relative gray vale to GAPDH/β-actin. (Mean ± SD, n = 3 independent experiments, data analyzed by Independent-samples t -test.) Statistical significance: ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Otenabant, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/otenabant/otenabant/pm38887179-176-46-47
    Average 90 stars, based on 1 article reviews
    otenabant - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    otenabant  (MedChemExpress)
    94
    MedChemExpress otenabant
    Effect of 3-arm antagonists in modulating GRAB eCB2.0 fluorescence in presence of 300 nM CP55940.
    Otenabant, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/otenabant/Otenabant/pmc11084632-210-32-33
    Average 94 stars, based on 1 article reviews
    otenabant - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    otenabant (cp-945598)  (Pfizer Inc)
    90
    Pfizer Inc otenabant (cp-945598)
    Update of major metabolic targets and potential monotherapy drugs under development for NAFLD/NASH
    Otenabant (Cp 945598), supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/otenabant/cp+945+598/pmc10531241-138-1-17
    Average 90 stars, based on 1 article reviews
    otenabant (cp-945598) - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    otenabant ( 5 )  (Pfizer Inc)
    90
    Pfizer Inc otenabant ( 5 )
    Update of major metabolic targets and potential monotherapy drugs under development for NAFLD/NASH
    Otenabant ( 5 ), supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/otenabant/otenabant+++5++/pmc06771026-556-1-10
    Average 90 stars, based on 1 article reviews
    otenabant ( 5 ) - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ASCs-ApoVs exhibited cross-species conservation and robust environmental resilience. ( A ) Western blot analysis of myofibroblast-related markers in HS-fibroblasts with freezing-thawing (for 3 times) ASCs-ApoVs, freezing-thawing ASCs-ApoVs with additional DNase I treatment, freezing-thawing ASCs-ApoVs with additional RNase A treatment. ( B ) Quantification of ( a ) COL1A1, ( b ) COL3A1, ( c ) COL3A1/COL1A1, ( d ) α-SMA, ( e ) CDC20, ( f ) Vimentin, and ( g ) TGF-β1 expression from ( A ) section by relative gray vale to GAPDH and the control group. (Mean ± SD, n = 3 independent experiments, data analyzed by one-way ANOVA with Tukey’s HSD.) ( C ) RT-qPCR results of ( a ) COL1A1 , ( b ) COL3A1 , ( c ) COL3A1/COL1A1 , ( d ) ACTA2 , ( e ) CDC20 , ( f ) VIM , and ( g ) TGFB1 in HS-fibroblasts with processed ASCs-ApoVs treatment (ASCs-ApoVs freezing-thawing for 3 times, freezing-thawing ASCs-ApoVs with additional DNase I treatment, freezing-thawing ASCs-ApoVs with additional RNase A treatment, freezing-thawing ASCs-ApoVs with additional Proteinase K treatment), normalized to GAPDH and the control group. (Mean ± SD, n = 3 independent experiments, data analyzed by one-way ANOVA with Tukey’s HSD.) ( D ) Western blot analysis of CDC20 expression in normal human fibroblasts (BJ-fibroblasts), human keratinocytes (HaCaT cells), and mouse oral mucosa epithelial cells. ( E ) Quantification of CDC20 expression from ( D ) section by relative gray vale to GAPDH/β-actin. (Mean ± SD, n = 3 independent experiments, data analyzed by Independent-samples t -test.) Statistical significance: ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

    Journal: Biomedicines

    Article Title: Adipose Stem Cell-Derived Apoptotic Vesicles Attenuate Hypertrophic Scarring by Targeting the CDC20/WNT Signaling Pathway

    doi: 10.3390/biomedicines14051083

    Figure Lengend Snippet: ASCs-ApoVs exhibited cross-species conservation and robust environmental resilience. ( A ) Western blot analysis of myofibroblast-related markers in HS-fibroblasts with freezing-thawing (for 3 times) ASCs-ApoVs, freezing-thawing ASCs-ApoVs with additional DNase I treatment, freezing-thawing ASCs-ApoVs with additional RNase A treatment. ( B ) Quantification of ( a ) COL1A1, ( b ) COL3A1, ( c ) COL3A1/COL1A1, ( d ) α-SMA, ( e ) CDC20, ( f ) Vimentin, and ( g ) TGF-β1 expression from ( A ) section by relative gray vale to GAPDH and the control group. (Mean ± SD, n = 3 independent experiments, data analyzed by one-way ANOVA with Tukey’s HSD.) ( C ) RT-qPCR results of ( a ) COL1A1 , ( b ) COL3A1 , ( c ) COL3A1/COL1A1 , ( d ) ACTA2 , ( e ) CDC20 , ( f ) VIM , and ( g ) TGFB1 in HS-fibroblasts with processed ASCs-ApoVs treatment (ASCs-ApoVs freezing-thawing for 3 times, freezing-thawing ASCs-ApoVs with additional DNase I treatment, freezing-thawing ASCs-ApoVs with additional RNase A treatment, freezing-thawing ASCs-ApoVs with additional Proteinase K treatment), normalized to GAPDH and the control group. (Mean ± SD, n = 3 independent experiments, data analyzed by one-way ANOVA with Tukey’s HSD.) ( D ) Western blot analysis of CDC20 expression in normal human fibroblasts (BJ-fibroblasts), human keratinocytes (HaCaT cells), and mouse oral mucosa epithelial cells. ( E ) Quantification of CDC20 expression from ( D ) section by relative gray vale to GAPDH/β-actin. (Mean ± SD, n = 3 independent experiments, data analyzed by Independent-samples t -test.) Statistical significance: ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

    Article Snippet: The temperature-cycled ASCs-ApoVs were then aliquoted into four treatment groups: 1 PBS control, 2 50 μg/mL proteinase K (MCE, HY-10871), 3 50 μg/mL RNase A (MCE, HY-129046A), and 4 8 μg/mL DNase I (Beyotime, D7073; 37 °C, 60 min incubation).

    Techniques: Western Blot, Expressing, Control, Quantitative RT-PCR

    Effect of 3-arm antagonists in modulating GRAB eCB2.0 fluorescence in presence of 300 nM CP55940.

    Journal: International Journal of Molecular Sciences

    Article Title: Pharmacological Evaluation of Cannabinoid Receptor Modulators Using GRAB eCB2.0 Sensor

    doi: 10.3390/ijms25095012

    Figure Lengend Snippet: Effect of 3-arm antagonists in modulating GRAB eCB2.0 fluorescence in presence of 300 nM CP55940.

    Article Snippet: Chemicals and Reagents: 2-AG (Cayman, Ann Arbor, MI, USA #62160), CP55940 (Cayman #13608), ACEA (Biotechne, Minneapolis, MN, USA: Tocris #1319), SR141716 (MedChem Express, New York, NY, USA: #HY14136), Taranabant (MedChem Express #HY10013), Otenabant (MedChem Express #HY-10871), Ibipinabant (MedChem Express HY-14791), and GAT228 and GAT229 (MilliporeSigma: Burlington, MA, USA #SML1952 and #SML1951).

    Techniques: Fluorescence

    Update of major metabolic targets and potential monotherapy drugs under development for NAFLD/NASH

    Journal: Hepatology Communications

    Article Title: Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention

    doi: 10.1097/HC9.0000000000000234

    Figure Lengend Snippet: Update of major metabolic targets and potential monotherapy drugs under development for NAFLD/NASH

    Article Snippet: , Otenabant (CP-945598) , Phase 1 , NASH , √ , NA , NA , NA , Pfizer , Aronne et al .

    Techniques: